NASDAQ:VXRT Vaxart Q2 2025 Earnings Report $0.42 +0.01 (+3.11%) As of 11:19 AM Eastern ProfileEarnings HistoryForecast Vaxart EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/AVaxart Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVaxart Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Vaxart Earnings HeadlinesVaxart (NASDAQ:VXRT) & Xenetic Biosciences (NASDAQ:XBIO) Head-To-Head ContrastJuly 12, 2025 | americanbankingnews.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Vaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comSee More Vaxart Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxart? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxart and other key companies, straight to your email. Email Address About VaxartVaxart (NASDAQ:VXRT) is a clinical‐stage biotechnology company focused on the development of orally administered recombinant vaccines delivered in tablet form. Utilizing its proprietary VAAST™ (Vaccine‐Assisted Antigen Presentation System Technology) platform, Vaxart aims to stimulate both mucosal and systemic immune responses without the need for injections. The company’s approach is designed to simplify distribution logistics, eliminate cold‐chain requirements, and improve patient compliance by offering needle‐free vaccination options. Vaxart’s pipeline includes oral vaccine candidates for respiratory and enteric diseases. Among its lead programs is an oral COVID‐19 vaccine candidate intended to bolster mucosal immunity at the point of viral entry. In addition, Vaxart is advancing oral formulations targeting influenza and norovirus, each intended to provide broad protection and ease of administration. The company has engaged in preclinical and clinical collaborations to assess immunogenicity, safety and potential for rapid scale‐up should regulatory approvals be obtained. Founded in 2010 and headquartered in South San Francisco, California, Vaxart leverages a multidisciplinary team with expertise in virology, immunology and pharmaceutical development. The company has established manufacturing partnerships to support tablet formulation and has explored global distribution channels to address unmet vaccine needs in both developed and emerging markets. Vaxart’s leadership team is led by Chief Executive Officer Andrei Floroiu, whose prior roles include senior finance positions at public biotechnology companies, and Chief Scientific Officer Dr. Rich Malley, who brings extensive experience in vaccine research and development.Written by Jeffrey Neal JohnsonView Vaxart ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
